Cargando…
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust
AIMS: The SARS‐CoV‐2 virus binds to the angiotensin‐converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients with hypertension or diabetes and may rai...
Autores principales: | Bean, Daniel M., Kraljevic, Zeljko, Searle, Thomas, Bendayan, Rebecca, Kevin, O'Gallagher, Pickles, Andrew, Folarin, Amos, Roguski, Lukasz, Noor, Kawsar, Shek, Anthony, Zakeri, Rosita, Shah, Ajay M., Teo, James T.H., Dobson, Richard J.B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301045/ https://www.ncbi.nlm.nih.gov/pubmed/32485082 http://dx.doi.org/10.1002/ejhf.1924 |
Ejemplares similares
-
Biological responses to COVID-19: Insights from physiological and blood biomarker profiles
por: Zakeri, Rosita, et al.
Publicado: (2021) -
Pre-existing cardiovascular disease rather than cardiovascular risk factors drives mortality in COVID-19
por: O’Gallagher, Kevin, et al.
Publicado: (2021) -
Diagnostic signature for heart failure with preserved ejection fraction (HFpEF): a machine learning approach using multi-modality electronic health record data
por: Farajidavar, Nazli, et al.
Publicado: (2022) -
Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020) -
The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)